CAS No. :	38304-91-5
Formula :	C₉H₁₅N₅O
M.W :	209.25
SMILES Code :	NC1=NC(N2CCCCC2)=CC(N)=[N+]1[O-]
Synonyms :	U10858; Loniten; Minoxidil, Loniten, Rogaine, U 10858
MDL No. :	MFCD00063409
InChI Key :	ZIMGGGWCDYVHOY-UHFFFAOYSA-N
Pubchem ID :	4201

GHS Pictogram:
Signal Word:	Warning
Hazard Statements:	H302-H315-H319-H332-H335
Precautionary Statements:	P261-P280-P305+P351+P338

Human dermal papilla cells (HDPCs)	0.0002	48 hours	Evaluate the effect of HL@Mi/NONOate on the proliferation of HDPCs. Results showed that the cell proliferation rate in the HL@Mi/NONOate group was 161.90%, significantly higher than the HL@Mi group (103.63%) and the control group.	Bioact Mater. 2023 Oct 11;32:190-205
Human Umbilical Vein Endothelial Cells (HUVECs)	0.0002	48 hours	Evaluate the effect of HL@Mi/NONOate on the proliferation of HUVECs. Results showed that the cell proliferation rate in the HL@Mi/NONOate group was 153.77%, significantly higher than the HL@Mi group (115.18%) and the control group.	Bioact Mater. 2023 Oct 11;32:190-205
human dermal papilla cells (DPCs)	0.5, 1, 2 mM	4 hours	To investigate the induction of HIF-1α protein by minoxidil, results showed that 2 mM minoxidil significantly induced HIF-1α protein expression.	Int J Mol Sci. 2017 Dec 25;19(1):53
human keratinocytes (HaCaT cells)	0.5, 1, 2 mM	4 hours	To investigate the induction of HIF-1α protein by minoxidil, results showed that 2 mM minoxidil significantly induced HIF-1α protein expression.	Int J Mol Sci. 2017 Dec 25;19(1):53
Adipose-derived stem cells (ASCs)	20 and 50 µM	2 days and 7 days	Minoxidil did not alter ASC proliferation but increased migration and tube formation	Int J Mol Sci. 2018 Feb 28;19(3):691
Caco-2 cells	80 µg/mL (382 µM)	120 minutes	Evaluate the permeability of minoxidil across Caco-2 cell monolayers, showing that tight junction modifiers (quercetin and sodium decanoate) significantly affect its permeability.	Pharmaceutics. 2022 Jun 27;14(7):1360

C57BL/6 mice	Androgenetic alopecia (AGA) model	Topical application	5% Minoxidil	Once daily for 28 days	Compare the hair regeneration effects of V-R-MN and Minoxidil in AGA model mice, with the V-R-MN group showing faster hair regeneration onset and improved hair quality.	Bioact Mater. 2024 Apr 23;38:95-108
Wistar rats	Single-pass intestinal perfusion model	Intestinal perfusion	80 µg/mL (382 µM)	1 hour perfusion followed by an additional 1 hour of perfusion, sampling every 10 minutes	Evaluate the permeability of minoxidil in different intestinal segments, showing that tight junction modifiers significantly affect its permeability.	Pharmaceutics. 2022 Jun 27;14(7):1360
Rat	Skin permeation model	Topical application	300 μg	Single dose, observed for 24 hours	Evaluate the skin permeation efficiency of HA-PLGA/MXD NPs, showing higher permeation efficiency of HA-PLGA NPs compared to PLGA NPs	Biomater Res. 2019 Oct 31;23:16
ICR mice		Topical application	5%	Single application, lasting 4 hours	To investigate the effect of minoxidil on VEGF and HIF-1α levels in the skin, results showed that minoxidil significantly elevated VEGF and HIF-1α levels in mouse skins.	Int J Mol Sci. 2017 Dec 25;19(1):53

NCT00283686	Kidney, Polycystic	Phase 3	Completed	-	United States, Colorado ... More >> University of Colorado Health Sciences Center Denver (Aurora), Colorado, United States, 800045 United States, Georgia Emory University School of Medicine Atlanta, Georgia, United States, 30322 United States, Kansas University of Kansas Medical Center Kansas City, Kansas, United States, 66160 United States, Massachusetts Tufts University-New England Medical Center Boston, Massachusetts, United States, 02111 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Ohio Cleveland Clinic Foundation Cleveland, Ohio, United States, 44195 Less <<
NCT00283686	-		Completed	-	-
NCT01227031	-		Unknown	July 2011	Taiwan ... More >> Taipei Medical University-Wan Fang Hospital Not yet recruiting Taipei, Taiwan Contact: Ren-Yu Tsai 886-2-29307930 ext 2980 b671022@tmu.edu.tw Less <<
NCT01852487	Androgenic Alopecia	Not Applicable	Completed	-	Korea, Republic of ... More >> Pusan National University Yangsan Hospital Yangsan, Gyeongsangnam-do, Korea, Republic of, 626-770 Less <<
NCT00418730	Androgenetic Alopecia	Phase 2	Completed	-	Germany ... More >> bioskin Institute for Dermatological Research and Development GmbH Hamburg, Germany, 20095 Less <<
NCT00684489	Hypertension	Not Applicable	Completed	-	-
NCT01643629	Androgenetic Alopecia	Phase 1 Phase 2	Unknown	November 2012	India ... More >> Kasiak Research Pvt Ltd Thane, Maharashtra, India, 400610 Less <<
NCT03331003	Alopecia	Not Applicable	Completed	-	-
NCT01325350	Alopecia Bald... More >>ness Less <<	Phase 2	Completed	-	United States, Oregon ... More >> Portland, Oregon, United States Germany Berlin, Germany Less <<
NCT02824380	Androgenic Alopecia	Phase 1	Completed	-	Korea, Republic of ... More >> Inje University Busan Paik Hospital Busan, Korea, Republic of Less <<
NCT01325337	Alopecia Alop... More >>ecia, Androgenetic Baldness Less <<	Phase 2	Completed	-	United States, Oregon ... More >> Portland, Oregon, United States Germany Berlin, Germany Less <<
NCT03351322	Female Pattern Baldness ... More >> Hair Loss Alopecia Less <<	Phase 2	Recruiting	March 2019	Taiwan ... More >> Taipei Veterans General Hospital Recruiting Taipei, Taiwan Contact: Chih-Chiang Chen, MD. PhD. 886-2-2871-2121 ext 3373 d-derm@vghtpe.gov.tw Principal Investigator: Chih-Chiang Chen, MD. PhD. Less <<
NCT01451125	Androgenetic Alopecia ... More >> Male Pattern Baldness Female Pattern Baldness Less <<	Phase 2	Completed	-	United States, Alabama ... More >> Radiant Research, Inc. Birmingham, Alabama, United States, 35209 United States, Arizona Radiant Research, Inc. Tucson, Arizona, United States, 85710 United States, Florida Radiant Research, Inc. Pinellas Park, Florida, United States, 33781 United States, Missouri Radiant Research, Inc. St Louis, Missouri, United States, 63141 Less <<
NCT01325337	-		Completed	-	-
NCT00607477	Treatment Induced Hypertension	Not Applicable	Terminated(Study has been term... More >>inated due to poor accrual.) Less <<	-	United States, Illinois ... More >> University of Chicago Chicago, Illinois, United States, 60637 Less <<
NCT02280603	Androgenetic Alopecia	Phase 1 Phase 2	Completed	-	Korea, Republic of ... More >> Catholic Medical Center Seoul, Dongdaemun-gu, Korea, Republic of, 130-709 Less <<
NCT01325350	-		Completed	-	-
NCT00175617	Female Pattern Hair Loss	Phase 2	Completed	-	Canada, British Columbia ... More >> UBC Division of Dermatology, Hair Research and Treatment Centre Vancouver, British Columbia, Canada, V6G 1Y6 Less <<
NCT02279823	Androgenetic Alopecia	Phase 2	Completed	-	United States, California ... More >> Therapeutics Clinical Research San Diego, California, United States, 92123 United States, Minnesota Minnesota Clinical Study Center Fridley, Minnesota, United States, 55432 United States, Texas DermResearch, Inc. Austin, Texas, United States, 78759 Less <<
NCT00607477	-		Terminated(Study has been term... More >>inated due to poor accrual.) Less <<	-	-
NCT02154503	Androgenetic Alopecia	Phase 1	Unknown	March 2017	Canada, British Columbia ... More >> The Skin Care Centre Recruiting Vancouver, British Columbia, Canada, V5Z 4E8 Principal Investigator: Jerry Shapiro, MD FRCPC Less <<
NCT01226459	Androgenetic Alopecia	Phase 3	Completed	-	United States, California ... More >> Axis Clinical Trials Los Angeles, California, United States, 90036 Axis Clinical Trials Los Angeles, California, United States, 90057 Therapeutics Clinical Research San Diego, California, United States, 92123 United States, Kansas Heartland Research Associates LLC Wichita, Kansas, United States, 67207 United States, Maryland Callender Skin & Laser Center Glenn Dale, Maryland, United States, 20769 United States, Michigan Michigan Center for Skin Care Research Clinton Township, Michigan, United States, 48038 United States, Minnesota Minnesota Clinical Study Center Fridley, Minnesota, United States, 55432 United States, New York New York University School of Medicine New York, New York, United States, 10016 Derm Research Center of New York Stony Brook, New York, United States, 11790 United States, Ohio Cleveland Clinic Cleveland, Ohio, United States, 44195 United States, Texas J&S Studies, Inc. College Station, Texas, United States, 77845 David A. Whiting, MD PA Dallas, Texas, United States, 75246 United States, Virginia The Education & Research Foundation Inc Lynchburg, Virginia, United States, 24501 France Hôpital Saint Jacques Service de Dermatologie Besançon, France, 25030 Germany Clinical Research Center for Hair and Skin Science Universitätsmedizin Berlin Berlin, Germany, 10117 Dermaticum Practice for Dermatology Freiburg, Germany, 79098 United Kingdom George Eliot Hospital Nuneaton, United Kingdom, CV10 7DJ Less <<
NCT01226459	-		Completed	-	-
NCT01662089	Female Pattern Alopecia	Phase 1 Phase 2	Unknown	December 2012	Thailand ... More >> Siriraj Hospital Recruiting Bangkok, Thailand, 10700 Contact: Rattapon Thuangtong, MD +662 419-7000 ext 4333 rattapongthuangtong@yahoo.com Less <<
NCT02460497	Female Pattern Hair Loss, Andr... More >>ogenic Alopecia Less <<	Not Applicable	Completed	-	United States, Texas ... More >> Stephens & Associates Richardson, Texas, United States, 75081 Less <<
NCT02483195	Female Androgenetic Alopecia	Phase 4	Withdrawn(PI indicating she wa... More >>s withdrawing her study submission due to lack of funding as of 6/20/2016) Less <<	August 2018	United States, Florida ... More >> UF Health Gainesville, Florida, United States, 32610 Less <<
NCT02460289	Male Pattern of Hair Loss, And... More >>rogenic Alopecia Less <<	Not Applicable	Completed	-	United States, Texas ... More >> Stephens & Associates Richardson, Texas, United States, 75081 Less <<
NCT03535233	Alopecia Areata	Phase 4	Completed	-	-
NCT01145625	-		Completed	-	-
NCT02283645	Chest Hair Enhancement	Phase 4	Unknown	August 2015	-
NCT02275832	Beard Enhancement	Phase 4	Completed	-	Thailand ... More >> MFL University Hospital (Bangkok) Bangkok, Thailand Less <<
NCT00876200	Williams Beuren Syndrome	Phase 2	Completed	-	France ... More >> Service de Cardiologie Pédiatrique, CHU Angers Angers, France, 49033 Service de Cardiologie, Hôpital Saint-André, CHU Bordeaux Bordeaux, France, 33075 Service de Néphrologie Pédiatrique, Hôpital Pellegrin, CHU Bordeaux Bordeaux, France, 33076 Service de Génétique Médicale, Hôpital Pellegrin, CHU Bordeaux Bordeaux, France Département de Pédiatrie, Hôpital Femme Mère Enfant Bron, France, 69677 Service de Cardiologie Pédiatrique, Hôpital Cardiovasculaire L. Pradel Bron, France, 69677 Service Cardiologie, CHU St Jacques Clermont-Ferrand, France, 63000 Département de Pédiatrie- Service de Cardiologie, CHU Grenoble Grenoble, France, 38043 Service de Néphrologie Pédiatrique, CHRU de Lille Lille, France, 59000 Service des Maladies Cardiovasculaires Infantiles et Congénitales, CHRU Lille Lille, France, 59000 Service de Cardiologie Infantile, CHU Nancy Nancy, France, 54511 Service de Cardiologie Pédiatrique, Hôpital Necker Enfants Malades Paris, France, 75015 Service de Physiologie, Explorations Fonctionnelles, Hôpital Robert Debré Paris, France, 75019 Unité de Pharmacologie Clinique, Hôpital Robert Debré Paris, France, 75019 Service de Pathologie Cardiaque Congénitale du Fœtus, de l'Enfant et de l'Adulte, Hôpital Haut Lévêque, CHU de Bordeaux Pessac, France, 33604 Service de Génétique Médicale, CHU La Milétrie Poitiers, France, 86021 Service de Cardiologie - Hôpital des Enfants Toulouse, France, 31059 Service de Néphrologie Pédiatrique - Hôpital des Enfants, CHU Toulouse Toulouse, France, 31059 Less <<
NCT01391156	Androgenetic Alopecia	Phase 3	Completed	-	Thailand ... More >> Mae Fah Luang University Hospital(Bangkok) Bangkok, Thailand Less <<
NCT00151515	Androgenetic Alopecia	Phase 3	Completed	-	United States, California ... More >> Pfizer Investigational Site La Jolla, California, United States, 92037 Pfizer Investigational Site San Francisco, California, United States, 94102 Pfizer Investigational Site Vallejo, California, United States, 94503 United States, Colorado Pfizer Investigational Site Denver, Colorado, United States, 80012 United States, Connecticut Pfizer Investigational Site New Haven, Connecticut, United States, 06510 United States, Minnesota Pfizer Investigational Site Fridley, Minnesota, United States, 55421 Pfizer Investigational Site Minneapolis, Minnesota, United States, 55401 United States, North Carolina Pfizer Investigational Site Durham, North Carolina, United States, 27701 United States, Ohio Pfizer Investigational Site Cincinnati, Ohio, United States, 45202 Pfizer Investigational Site Cleveland, Ohio, United States, 44101 United States, Oregon Pfizer Investigational Site Portland, Oregon, United States, 97201 United States, Pennsylvania Pfizer Investigational Site Hershey, Pennsylvania, United States, 17033 United States, Texas Pfizer Investigational Site Austin, Texas, United States, 78701 Pfizer Investigational Site Dallas, Texas, United States, 75201 United States, Utah Pfizer Investigational Site Salt Lake City, Utah, United States, 84101 Less <<
NCT01145625	Alopecia	Phase 3	Completed	-	United States, Arkansas ... More >> Burke Pharmaceutical Research Hot Springs, Arkansas, United States, 71913 United States, Minnesota University of Minnesota Minneapolis, Minnesota, United States, 55455 United States, New Mexico Academic Dermatology Associates Albuquerque, New Mexico, United States, 87106 United States, North Carolina Duke University Medical Center Durham, North Carolina, United States, 27710 United States, Oregon Oregon Medical Research Center, P.C. Portland,, Oregon, United States, 97223 NW Dermatology and Research Center Portland, Oregon, United States, 97210 United States, Texas DermResearch, Inc Austin, Texas, United States, 78759 United States, Utah Dermatology Research Center, Inc. Salt Lake City, Utah, United States, 84124 Canada, British Columbia The Skin Care Centre Vancouver, British Columbia, Canada, V5Z 4E8 France Centre de Santé Sabouraud Paris, Île-de-France, France, 75010 Germany Klinik für Dermatologie, Venerologie und Allergologie, Clinical Research Center for Hair and Skin Science Berlin, Germany, 10117 United Kingdom Royal Hallamshire Hospital Sheffield, South Yorkshire, United Kingdom, S10 2JF Less <<
NCT01319370	Androgenetic Alopecia	Phase 2	Completed	-	Germany ... More >> Charité-Universitätsmedizin Berlin, Clinical Research Center for Hair and Skin Science, Dept. of Dermatology, Venereology and Allergy Berlin, Germany, 10117 Less <<
NCT01900041	Female Pattern Hair Loss ... More >> Androgenetic Alopecia (AGA) Ludwig Type 1 Ludwig Type 2 Less <<	Phase 2	Completed	-	Russian Federation ... More >> State Scientific Center of Dermatology and Cosmetology Moscow, Russian Federation, 107076 Moscow Scientific Clinical Center of Dermatology and Cosmetology Moscow, Russian Federation, 119071 Less <<
NCT00958750	Androgenetic Alopecia ... More >> Female Pattern Hair Loss Less <<	Phase 3	Completed	-	Germany ... More >> Charité-Universitaetsmedizin; Clinical Research Center for Hair and Skin Science Berlin, Germany, 10117 Less <<
NCT01924000	Eyebrow Hypotrichosis ... More >> Thin Eyebrow Less <<	Phase 4	Completed	-	Thailand ... More >> Mae Fah Luang University Hospital (Bangkok) Bangkok, Thailand Less <<
NCT01672307	Hypotrichosis of Eyebrows ... More >> Thinning Eyebrows Less <<	Phase 4	Completed	-	Thailand ... More >> MFL University Hospital (Bangkok) Bangkok, Thailand, 10110 Less <<
NCT01655108	Female Pattern Alopecia	Phase 3	Unknown	December 2013	Brazil ... More >> University of Brasilia Brasilia, Distrito Federal, Brazil, 71917-720 Less <<
NCT03488108	Alopecia	Phase 1 Phase 2	Active, not recruiting	December 31, 2019	United States, Florida ... More >> Mayo Clinic Florida Jacksonville, Florida, United States, 32224 Less <<
NCT03753113	Androgenetic Alopecia	Phase 3	Recruiting	May 2019	Iran, Islamic Republic of ... More >> Department of Dermatology, Sina Hospital Recruiting Tabriz, East Azerbaijan, Iran, Islamic Republic of Contact: Hamideh Azimi Alamdari, MD +98 41 3541 2151 hamide_azimi@yahoo.com Principal Investigator: Farid Masoud, PharmD Less <<
NCT01309191	Androgenetic Alopecia	Not Applicable	Completed	-	United States, Ohio ... More >> Skin Study Center, UH Case Medical Center Cleveland, Ohio, United States, 44106 Less <<
NCT02206802	-		Completed	-	United States, Arizona ... More >> Physicians Hair Institute Tucson, Arizona, United States, 85719 United States, Tennessee Tennessee Clinical Research Center Nashville, Tennessee, United States, 37215 Australia Sinclair Dermatology East Melbourne, Australia, 3002 India LTM Medical College & Hospital Mumbai, India, 400022 Italy Istituto Medico Tricologico/Studi Life Cronos Florence, Italy, 50127 Less <<
NCT02198261	-		Completed	-	United States, Arizona ... More >> Physicians Hair Institute Tucson, Arizona, United States, 85719 United States, Tennessee Tennessee Clinical Research Center Nashville, Tennessee, United States, 37215 Australia Sinclair Dermatology East Melbourne, Australia, 3002 India LTM Medical College & Hospital Mumbai, India, 400022 Italy Istituto Medico Tricologico/Studi Life Cronos Florence, Italy, 50127 Less <<
NCT01650272	Objective (Goal) ... More >> Self-Assessment Adverse Effects Less <<	Phase 1 Phase 2	Unknown	April 2013	Thailand ... More >> Siriraj Hospital Recruiting Bangkok, Thailand, 10700 Contact: Kanchalit Thanomkitti, MD +668 9529 0298 kanchalitt@hotmail.com Principal Investigator: Rattapon Thuangtong,, MD Less <<
NCT03528772	Anal Fissure	Not Applicable	Recruiting	August 30, 2019	Egypt ... More >> Mansoura university hospital Recruiting Mansourah, Dakahlia, Egypt, 35516 Contact: Sameh Emile, M.D 01006267150 sameh200@hotmail.com Contact: Sameh H Emile, M.D. Less <<
NCT02486848	Female Pattern Hair Loss ... More >> Androgenetic Alopecia Less <<	Not Applicable	Withdrawn	December 2016	Italy ... More >> Istituto Scienze Dermatologiche Florence, Tuscany, Italy Less <<
NCT05864885	Androgenetic Alopecia	PHASE1	NOT_YET_RECRUITING	2023-07-17	-
NCT05272462	Ovarian Cancer	PHASE2	RECRUITING	2024-12-31	Loyola University Medical Cent... More >>er, Maywood, Illinois, 60153, United States Less <<

{[proInfo.proName]}

CAS No.: 38304-91-5

{[proInfo.proName]}

CAS No.: 38304-91-5

Alternative Products

Product Details of Minoxidil

Safety of Minoxidil

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Bio Calculators
Preparing Stock Solutions		1mg	5mg	10mg
Preparing Stock Solutions	1 mM 5 mM 10 mM	4.78mL 0.96mL 0.48mL	23.89mL 4.78mL 2.39mL	47.79mL 9.56mL 4.78mL
Dissolving Methods	Animal experiment Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn: in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day; The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound. Protocol 1 Protocol 2 The prepared working fluid is recommended to be prepared now and used up as soon as possible in a short period of time. The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed